SRTS Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

8.35M

-36.14%

-0.055

-161.11%

8.23M

-1.35%

-0.050

-68.75%

9.25M

+26.46%

-0.010

-83.33%

Estimates Revision

The market is revising No Change the revenue expectations for Sensus Healthcare, Inc. (SRTS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by 20.63%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

No Change

0.00%

In Past 3 Month

Stock Price

Go Up

+20.63%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast SRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SRTS is 7.00 USD with a low forecast of 6.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 3.800

Low

6.00

Averages

7.00

High

8.00

Current: 3.800

Low

6.00

Averages

7.00

High

8.00

H.C. Wainwright

Buy

downgrade

$12 -> $8

2025-08-12

Reason

H.C. Wainwright

Price Target

$12 -> $8

2025-08-12

downgrade

Buy

Reason

H.C. Wainwright lowered the firm's price target on Sensus Healthcare to $8 from $12 and keeps a Buy rating on the shares. The firm cites the company's Q2 sales miss for the target cut.

Lake Street

Buy

downgrade

$13 -> $6

2025-08-08

Reason

Lake Street

Price Target

$13 -> $6

2025-08-08

downgrade

Buy

Reason

Lake Street lowered the firm's price target on Sensus Healthcare to $6 from $13 and keeps a Buy rating on the shares. Q2 results fell below expectations and the firm's conclusion from its survey work that suggested upside to the quarter "was flat-out wrong," the analyst tells investors. However, the firm still believes "all roads ultimately lead to greater certainty and should benefit Sensus," the analyst added.

Maxim

Buy

downgrade

$14 -> $10

2025-05-19

Reason

Maxim

Price Target

$14 -> $10

2025-05-19

downgrade

Buy

Reason

Maxim lowered the firm's price target on Sensus Healthcare to $10 from $14 and keeps a Buy rating on the shares. The firm is updating its estimates to reflect the company's Q1 results and its expectations as well as citing its shift from a pure capital sales model to include its Fair Deal Agreement model, the analyst tells investors in a research note.

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$12

2025-04-04

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$12

2025-04-04

Reiterates

Strong Buy

Reason

Lake Street

Ben Haynor

Strong Buy

Maintains

$18 → $13

2025-03-11

Reason

Lake Street

Ben Haynor

Price Target

$18 → $13

2025-03-11

Maintains

Strong Buy

Reason

Conference call with management will be held on March 4 at 3:30 pm hosted by Lake Street.

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$11 → $12

2025-02-10

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$11 → $12

2025-02-10

Maintains

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Sensus Healthcare Inc (SRTS.O) is -30.92, compared to its 5-year average forward P/E of 9.78. For a more detailed relative valuation and DCF analysis to assess Sensus Healthcare Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

9.78

Current PE

-30.92

Overvalued PE

59.66

Undervalued PE

-40.10

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-72.87

Current EV/EBITDA

-8.95

Overvalued EV/EBITDA

315.09

Undervalued EV/EBITDA

-460.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.58

Current PS

1.68

Overvalued PS

3.61

Undervalued PS

1.55

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

N/A

ROIC

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 4278.93% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areBuying! The selling amount has increased 4278.93% over the last month.

Sold

Bought

SRTS News & Events

Events Timeline

No data

News

9.5

11-07NASDAQ.COM

Sensus Healthcare, Inc. (SRTS) Announces Q3 Loss While Exceeding Revenue Projections

5.0

11-06Newsfilter

Sensus Healthcare Recognized as One of TIME's Growth Leaders in America for 2026

5.0

10-31Newsfilter

Sensus Healthcare Reports the Death of Director Bill McCall

People Also Watch

Frequently Asked Questions

What is Sensus Healthcare Inc (SRTS) stock price today?

The current price of SRTS is 3.8 USD — it has increased 2.98 % in the last trading day.

What is Sensus Healthcare Inc (SRTS)'s business?

Sensus Healthcare, Inc. is a medical device company that is engaged in the development and delivery of non-invasive treatments for skin cancer and keloids. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.

What is the price predicton of SRTS Stock?

What is Sensus Healthcare Inc (SRTS)'s revenue for the last quarter?

Sensus Healthcare Inc revenue for the last quarter amounts to 6.88M USD, decreased -22.12 % YoY.

What is Sensus Healthcare Inc (SRTS)'s earnings per share (EPS) for the last quarter?

Sensus Healthcare Inc. EPS for the last quarter amounts to -0.06 USD, decreased -185.71 % YoY.

What changes have occurred in the market's expectations for Sensus Healthcare Inc (SRTS)'s fundamentals?

How many employees does Sensus Healthcare Inc (SRTS). have?

Sensus Healthcare Inc (SRTS) has 35 emplpoyees as of December 17 2025.

What is Sensus Healthcare Inc (SRTS) market cap?

Today SRTS has the market capitalization of 62.42M USD.